Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study
- PMID: 37420008
- DOI: 10.1038/s41366-023-01328-y
Associations of obesity phenotypes with weight change, cardiometabolic benefits, and type 2 diabetes incidence during a lifestyle intervention: results from the PREVIEW study
Abstract
Background/objectives: Some individuals with overweight/obesity may be relatively metabolically healthy (MHO) and have a lower risk of cardiovascular disease than those with metabolically unhealthy overweight/obesity (MUO). We aimed to compare changes in body weight and cardiometabolic risk factors and type 2 diabetes incidence during a lifestyle intervention between individuals with MHO vs MUO.
Methods: This post-hoc analysis included 1012 participants with MHO and 1153 participants with MUO at baseline in the randomized trial PREVIEW. Participants underwent an eight-week low-energy diet phase followed by a 148-week lifestyle-based weight-maintenance intervention. Adjusted linear mixed models and Cox proportional hazards regression models were used.
Results: There were no statistically significant differences in weight loss (%) between participants with MHO vs MUO over 156 weeks. At the end of the study, weight loss was 2.7% (95% CI, 1.7%-3.6%) in participants with MHO and 3.0% (2.1%-4.0%) in those with MUO. After the low-energy diet phase, participants with MHO had smaller decreases in triglyceride (mean difference between MHO vs MUO 0.08 mmol·L-1 [95% CI, 0.04-0.12]; P < 0.001) but similar reductions in fasting glucose and HOMA-IR than those with MUO. However, at the end of weight maintenance, those with MHO had greater reductions in triglyceride (mean difference -0.08 mmol·L-1 [-0.12--0.04]; P < 0.001), fasting glucose, 2-hour glucose (difference -0.28 mmol·L-1 [-0.41--0.16]; P < 0.001), and HOMA-IR than those with MUO. Participants with MHO had smaller decreases in diastolic blood pressure and HbA1c and greater decreases in HDL cholesterol after weight loss than those with MUO, whereas the statistically significant differences disappeared at the end of weight maintenance. Participants with MHO had lower 3-year type 2 diabetes incidence than those with MUO (adjusted hazard ratio 0.37 [0.20-0.66]; P < 0.001).
Conclusions: Individuals with MUO had greater improvements in some cardiometabolic risk factors during the low-energy diet phase, but had smaller improvements during long-term lifestyle intervention than those with MHO.
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
Cardiovascular Risk Factors Associated With the Metabolically Healthy Obese (MHO) Phenotype Compared to the Metabolically Unhealthy Obese (MUO) Phenotype in Children.Front Endocrinol (Lausanne). 2020 Feb 7;11:27. doi: 10.3389/fendo.2020.00027. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32117055 Free PMC article.
-
Long-term impact of the metabolic status on weight loss-induced health benefits.Nutr Metab (Lond). 2022 Mar 28;19(1):25. doi: 10.1186/s12986-022-00660-w. Nutr Metab (Lond). 2022. PMID: 35346256 Free PMC article.
-
Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: associations with inflammatory and cardiometabolic markers in 4391 subjects.Diabetes Metab. 2014 Nov;40(5):347-55. doi: 10.1016/j.diabet.2014.02.007. Epub 2014 May 5. Diabetes Metab. 2014. PMID: 24811744
-
Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.Ann Hepatol. 2020 Jul-Aug;19(4):359-366. doi: 10.1016/j.aohep.2020.03.001. Epub 2020 Mar 21. Ann Hepatol. 2020. PMID: 32349939 Review.
-
Metabolic phenotyping in people living with obesity: Implications for dietary prevention.Rev Endocr Metab Disord. 2023 Oct;24(5):825-838. doi: 10.1007/s11154-023-09830-4. Epub 2023 Aug 15. Rev Endocr Metab Disord. 2023. PMID: 37581871 Free PMC article. Review.
References
-
- Bluher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41:405–20. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous